HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Should ustekinumab really be used as first-line biological therapy in pityriasis rubra pilaris?

AuthorsR Balestri, F Bardazzi, A Antonucci
JournalThe British journal of dermatology (Br J Dermatol) Vol. 163 Issue 4 Pg. 896-7; author reply 897-8 (Oct 2010) ISSN: 1365-2133 [Electronic] England
PMID20662839 (Publication Type: Comment, Letter)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Dermatologic Agents
  • Immunosuppressive Agents
  • Ustekinumab
Topics
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Dermatologic Agents (therapeutic use)
  • Humans
  • Immunosuppressive Agents (therapeutic use)
  • Off-Label Use
  • Pityriasis Rubra Pilaris (drug therapy)
  • Ustekinumab

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: